Biotech news

Reset all filters
Geography
Company
Refine search
Patents for plants in Mexico
Americas
Genetically modified plants, hybrid seeds and plants obtained from such seeds are usually granted patent protection in Mexico as they are not created by ‘essentially biological’ processes, as Fernando Rincón of Becerril, Coca & Becerril reports.   3 March 2015
New recipes for Tomatoes and Broccoli
Biotech
Controversial patents covering a fruit and a vegetable are awaiting their fate at the Enlarged Board of Appeal. LSIPR examines the likelihood of their succeeding.   3 March 2015
Americas
Law firm Kaye Scholer has added a team of three life sciences and technology lawyers to its intellectual property group.   13 February 2015
Americas
Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe.   30 January 2015
Americas
The US Food and Drug Administration has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.   5 January 2015
Americas
Law firm Fitzpatrick, Cella, Harper, & Scinto will begin the New Year with three new faces in its partnership.   19 December 2014
Americas
A US biotechnology company that was on the winning side of an EU court ruling surrounding the patentability of certain organisms has said it “clears the way” for patents in Europe.   19 December 2014
Americas
The US Patent and Trademark Office has issued new guidance for determining what claims are eligible for patenting, with one lawyer saying it could “muddy the waters”.   17 December 2014
Americas
Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).   9 December 2014
Pharma
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP.   26 November 2014